The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Shame to see it being hammered in this way - no great for me since I hold 100k of these. But on the bright side.. http://www.proactiveinvestors.co.uk/companies/news/173408/busy-abzena-makes-strong-start-to-the-year-173408.html
Sorry I was dictating my last message and I meant to say FUNDS not phones
Yes I agree and I think the phones may come from a partner preferably American
before the latest RNSs http://www.edisoninvestmentresearch.com/research/report/abzena734423/preview/?utm_source=edison&utm_medium=eqs_press_release&utm_campaign=Abzena_02022017
As with most Pharmas so no great surprise. They can't live on fresh air.
Yes, you missed the bit about fundraising
The ramping crew are stuck in Miners and Oil....
The RNS reads as good news to me...not amazing but definitely positive. Am I missing something??
to investors at the Biotech Capital Conference on 9 Mar 2016 https://www.youtube.com/watch?v=KdveLjuJ-o8
Not to like about the RNS's ? We should be hitting 50p ! So much to come.
The good news keeps on coming.
Future looks bright and a lot going on in the background to develop further revenue streams. Happy holding here for sure.
Antibody manufacturing development agreement Tue, 21st Feb 2017 07:01 RNS Number : 3728X Abzena PLC 21 February 2017 Abzena plc Antibody manufacturing development agreement signed with UCL Cambridge, UK, 21 February 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a manufacturing agreement with University College London ('UCL'), one of the world's leading universities. Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the 'Abzena inside' Composite Human Antibody™ technology. Under earlier agreements with UCL, Abzena conducted the antibody humanization and developed the manufacturing cell line for Magacizumab. In this latest service agreement Abzena will manufacture Magacizumab at its biomanufacturing facility in San Diego, CA, USA. This programme is the first to proceed with Abzena through each of the phases of humanization, cell line development and into manufacture, thus illustrating Abzena's expanded capabilities in the discovery, development and manufacture of biopharmaceutical products for its partners across its UK and US operations. Magacizumab is an 'Abzena inside' product that is being developed by the UCL Institute of Ophthalmology for the treatment of neovascular (or 'wet') age-related macular degeneration (AMD). This is a condition affecting older people that can lead to loss of vision due to abnormal blood vessel growth. The antibody targets LRG1 (leucine-rich alpha-2-glycoprotein 1) which researchers at UCL identified as having a role in promoting the growth of pathological blood vessels. The project is funded by the Medical Research Council's Developmental Pathway Funding Scheme. UCL Business, the technology commercialisation company of UCL, currently owns the patents for Magacizumab. Under the previous antibody humanization agreement with UCL, a milestone payment will become due to Abzena during clinical development of Magacizumab. Dr John Burt, Abzena's CEO, commented: "Being able to support the progression of Magacizumab towards the clinic is an important opportunity. This is the second 'Abzena inside' product that will utilise our San Diego biomanufacturing facility, demonstrating how our expanded contract manufacturing capabilities enable Abzena to earn additional service revenue from products created with our technologies." Professors Stephen Moss and John Greenwood at the UCL Institute of Ophthalmology, whose team identified LRG1 as a target for Magacizumab therapy, commented: "It is very gratifying to be embarking on this next stage of Magacizumab's development and to be continuing our work with Abzena to drive forward this exciting novel approach for the treatment of neovascular AMD."
2xrns's today... very nice.
Until there's news here, this ain't moving guv'nor.
They are buys in the red. Appears to be the tipping point to go back up. Let's see.
Whether there's some confusion around the recording of 'buys' and 'sells' today. Given that this is an extremely illiquid share, I'd be surprised to see it up on the basis of more sells than buys - as has been recorded. GLA
Slowly. Be good to have some news. Still to be revealed is the partner in the $300 deal. Listened to the CEO interview yesterday - sounds very upbeat and optimistic for 2017. GLA
Suddenly all will be revealed we hope.
I've never known a company to release RNS of research reports before. Not sure how I feel about it. I tend to prefer the BOD to be getting their heads down and focusing on the growth of the company - and of course the SP.
London, UK, 8 February 2017 Edison issues outlook on Abzena (ABZA) Abzena has recently achieved a significant licensing deal for its proprietary site-specific ThioBridge antibody drug conjugate (ADC) linker technology with a San Diego-based biopharmaceutical company. The agreement covers the use of ThioBridge in up to 10 ADCs across a wide range of indications and a service agreement. This provides important validation of Abzena's proprietary ADC technology and hybrid business model. Our rNPV valuation increases to £117m following inclusion of the 10 ADCs now being developed through this deal. We have increased our valuation to £117m (from £112m) or 85p per share (vs 82p). This is principally due to the inclusion of the 10 potential ADC products resulting from the recent (January 2017) ThioBridge agreement. We expect Abzena to gain greater deal economics from its ADC products due to the greater technological and IP input resulting from ThioBridge and therefore include a higher royalty rate (2.5%) than its antibodies developed using its Composite Human Antibody technologies (1%). We believe Abzena is well positioned to grow its integrated service offering and, as its Abzena inside products move through the clinic and onto the market, we expect upside to our current estimates.
a reminder RNS for anyone building up a holding.. Maybe a precursor.. All to come.
There you go. Back down to 40p circa.
It's the IPO at 81p and further raise at 60p keeps me settled, big names holding these who'll want returns
We all make these mistakes (though not all admit to them) - I bought a tranche at 59p - then at 57p, then at 40p ..then, as you know, today at 43p (by far the largest purchase of the 4). I do, however, think there's not much downside to this share now and I share the belief that on the advent of news (which I thought might come today or Mon - given the movement) it should move upwards very quickly because of its illiquidity. I still believe this; although when news will arrive (and indeed whether it will be positive) is anyone's guess. GLA